Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in Escherichia coli for the Development of Neutralizing Antibody Assay

The ongoing COVID-19 pandemic has resulted from widespread infection by the SARS-CoV-2 virus. As new variants of concern continue to emerge, understanding the correlation between the level of neutralizing antibodies (NAb) and clinical protection from SAR-CoV-2 infection could be critical in planning...

Descripción completa

Detalles Bibliográficos
Autores principales: Tantiwiwat, Termsak, Thaiprayoon, Apisitt, Siriatcharanon, Ake-kavitch, Tachaapaikoon, Chakrit, Plongthongkum, Nongluk, Waraho-Zhmayev, Dujduan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472194/
https://www.ncbi.nlm.nih.gov/pubmed/36103078
http://dx.doi.org/10.1007/s12033-022-00563-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472194/
https://www.ncbi.nlm.nih.gov/pubmed/36103078
http://dx.doi.org/10.1007/s12033-022-00563-4

Ejemplares similares